AVIR Atea Pharmaceuticals Inc

$AVIR · $HTGC 💰 Atea Pharmaceuticals, Inc. entered into a credit facility agreement with Hercules Capital, Inc. for up to $200 million to strengthen its financial position and support commercial-related activities ahead of a U.S. launch of bemnifosbuvir/ruzasvir. Selected from hundreds of headlines

$AVIR Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 24.53% YoY • Atea Pharmaceuticals believes existing resources, including $65M borrowed, will fund planned operations into mid-2028; based on current plans, it does not anticipate product sales revenue for the foreseeable future.

$AVIR 🏥 Atea Pharmaceuticals, Inc. reported that its Phase 3 C-BEYOND trial of BEM/RZR for chronic hepatitis C virus infection achieved primary and secondary endpoints. Actionable market event

$AVIR 10:12 AM EST, 11/09/2026 (MT Newswires) -- Atea Pharmaceuticals(AVIR) said Monday that it has signed an agreement with Hercules Capital(HTGC) to secure a credit facility for up to $200 million. The company said it received $65 million at closing and can secure an additional $105 million by meeting certain milestones. It could receive $30 million more on request. Atea said the facility will mature in 60 months and includes a 48-month interest-only period that could be extended to 60 months upon meeting a certain commercial milestone. The financing will give the company flexibility to help launch bemnifosbuvir in the United States to treat chronic hepatitis C, it said.